Topological Latent Manifold Model (TLMM) v7.2 extends the Amyloid–Blood Flow (ABF) causal cascade from a harmonized synthetic validation framework toward a comprehensive prospective clinical validation and translational framework. Unlike previous versions, TLMM v7.2 does not introduce a new causal architecture. Instead, it specifies how the established ABF cascade Amyloid-β → Tau Pathology → Blood–Brain Barrier → Blood Flow → Network Dysfunction → Viability Risk Index should be evaluated using: prospective multi-center cohort studies real-world causal structure learning latent confounder modeling longitudinal validation cross-cohort generalization abstention-calibrated uncertainty assessment privacy-preserving federated validation interpretable clinical decision support integrated system-level validation dashboards The validation framework expands the previous C1–C12 falsifiability battery into a C1–C13 framework, introducing Clinical Utility & Actionability (C13) while reorganizing the validation criteria into four domains: Causal Discovery Validity Temporal & Multiscale Validity Robustness & Generalization Safety, Fairness & Clinical Utility This repository contains: the complete TLMM v7.2 manuscript, sixteen publication-quality figures, an illustrative Python demonstration, documentation describing the proposed evaluation protocol. Important Notice All cohort sizes, quantitative metrics, validation scores, and experimental results contained in this repository are illustrative synthetic demonstrations intended solely for methodological specification. They do not represent clinical performance estimates derived from real patient data and do not constitute medical advice or clinical recommendations. TLMM v7.2 establishes a reproducible translational framework linking causal discovery, prospective validation, and precision structural medicine, providing a roadmap for future real-world multi-institutional validation.
Koji Okino (Sat,) studied this question.